Cancer prevention research 2009; 14(1): 20-27
Published online March 30, 2009
© Korean Society of Cancer Prevention
Young Eun Choi1,2, Chang Hoon Cho1,2, Hye Ok Kim1,2, Yong Hwa Jo1,2, Jun-Kyu Song1,2, Hyung Hwan Baik1,2, Wonchae Choe1,2, Insug Kang1,2 and Kyung-Sik Yoon1,2
Tamoxifen (Tam) is widely used in chemotherapy of breast cancer. It inhibits proliferation and induces apoptosis of breast cancer cells by estrogen receptor (ER)-dependent modulation of gene expression. ER involves with AMPK and MAPK pathway. Ghrelin is growth hormone and binds to growth hormone secreatagogue receptor1 (GHSR-1) that have estrogen receptor similar pathway. We studied to Tamoxifen, Estadiol & Ghrelin effects by MTT assay for cell viability and western blot for ERK/p38 phosphorylation in ER-positive MCF-7 (ER+) and ER-negative MDA-MB231 (ER−). We showed to MCF-7 cell death induction by Tamoxifen dose-dependent manner. But we can see inhibition of Tamoxifen effect by Estradiol and Ghrelin. ERK phosphorylation increased 2.9∼18.5-fold by dose-dependent Tamoxifen in both ER+ MCF-7 cells and 7.8-fold by 7ՌM Tamoxifen treatment in ER− MDA-MB231 cells. ERK phosphorylation was induced by Estadiol and Ghrelin in only ER+ MCF-7 cells, but p38 phosphorylation was not affected by Estradiol, Ghrelin and Tamoxifen in breast cancer cells. In conclusion, ERK activation of MAPK by Tamoxifen for cell death and Ghrelin in ER-positive MCF-7 cell line was observed. (Cancer Prev Res 14, 20-27, 2009)
Keywords: MCF7, MDA-MB231, Breast cancer, Tamoxifen, Ghrelin, Estrogen receptor
Cassandra Winz, Nanjoo Suh
J Cancer Prev 2021; 26(1): 18-24 https://doi.org/10.15430/JCP.2021.26.1.18Yanymee N. Guillen-Quispe, Su-Jung Kim, Soma Saeidi, Gyo-Jin Choi, Chaithanya Chelakkot, Tianchi Zhou, Sang-Beom Bang, Tae-Won Kim, Young Kee Shin, Young-Joon Surh
J Cancer Prev 2024; 29(4): 129-139 https://doi.org/10.15430/JCP.24.031Dessiet Oma, Maria Teklemariam, Daniel Seifu, Zelalem Desalegn, Endale Anberbir, Tamrat Abebe, Solomon Mequannent, Solomon Tebeje, Wajana Lako Labisso
J Cancer Prev 2023; 28(2): 64-74 https://doi.org/10.15430/JCP.2023.28.2.64